Калкулатор за PT-141

What Is PT-141?

PT-141, also known by its pharmaceutical name Bremelanotide, is a cyclic heptapeptide melanocortin receptor agonist with a uniquely central mechanism of action that distinguishes it fundamentally from all other pharmacological approaches to sexual dysfunction. Unlike PDE5 inhibitors such as sildenafil (Viagra) or tadalafil (Cialis), which act peripherally by relaxing vascular smooth muscle to increase genital blood flow, PT-141 acts directly within the central nervous system — specifically at melanocortin receptors MC3R and MC4R in the hypothalamus and limbic system.

This distinction has significant clinical implications. PDE5 inhibitors require sexual arousal to produce an effect; they facilitate the vascular response to stimulation but do not initiate desire or motivation. PT-141, by engaging melanocortin receptors in the brain regions governing sexual motivation and reward, activates the central drive component of the sexual response cycle. This mechanism is why PT-141 has shown efficacy in populations where PDE5 inhibitors fail — including women with hypoactive sexual desire disorder (HSDD), where the primary deficit is in desire rather than vascular response.

PT-141 was developed as a derivative of Melanotan II (MT-II), a synthetic analog of alpha-melanocyte-stimulating hormone (alpha-MSH). Researchers studying MT-II for its tanning properties incidentally discovered profound effects on sexual arousal during early human trials. Subsequent medicinal chemistry work produced PT-141 — a modified cyclic structure with reduced MC1R affinity (minimizing pigmentation effects) and preserved MC3R/MC4R activity. In 2019, the U.S. Food and Drug Administration approved an intranasal formulation of Bremelanotide under the trade name Vyleesi for the treatment of premenopausal women with acquired, generalized HSDD — the first and only centrally acting drug approved for female sexual dysfunction.

You can find PT-141 at BergdorfBio, available for research purposes.

Mechanism of Action in Detail

Melanocortin Receptor Pharmacology

The melanocortin system encompasses five receptor subtypes (MC1R through MC5R), each with distinct tissue distributions and physiological roles. PT-141 primarily engages:

• MC3R:Expressed in the hypothalamus and limbic system; involved in energy homeostasis, feeding behavior, and the regulation of sexual function. MC3R agonism is thought to contribute to the motivational component of PT-141's effect.
• MC4R:The primary mediator of PT-141's pro-sexual effects. MC4R is densely expressed in the paraventricular nucleus (PVN) of the hypothalamus, a region governing autonomic sexual reflexes including penile erection and vaginal lubrication. MC4R activation in the PVN stimulates oxytocin release, which further drives the downstream sexual response.

MC1R, which governs skin pigmentation (the receptor responsible for MT-II's tanning effects), has significantly lower affinity for PT-141 compared to its parent compound. This selective profile makes PT-141 substantially less likely to cause the unintended pigmentation changes observed with Melanotan II at equivalent doses.

Downstream Signaling and Oxytocin Release

MC4R activation in the PVN triggers a cascade: oxytocin neurons are stimulated, increasing central and peripheral oxytocin levels. Oxytocin, in addition to its well-known role in social bonding, is a potent mediator of sexual arousal, lubrication, and orgasmic response in both sexes. The dopaminergic pathways in the mesolimbic system are also modulated by melanocortin signaling, contributing to the enhanced motivational and reward aspects of sexual desire that PT-141 users report. This multi-pathway central activation explains why PT-141's effect quality differs from PDE5 inhibitors — users describe not just functional improvement but increased sexual motivation and interest.

Dosage Calculation

Precise dose calculation is essential when working with PT-141. For a standard 10 mg vial reconstituted with 2 ml of bacteriostatic water (BAC water), the concentration is:

10 mg / 2 ml = 5 mg/ml

At this concentration, the research dose range of 0.5–2 mg translates to the following injection volumes on a U100 insulin syringe:

• 0.5 mg dose: 0.5 ÷ 5 = 0.10 ml (10 units)
• 1 mg dose: 1 ÷ 5 = 0.20 ml (20 units)
• 1.5 mg dose: 1.5 ÷ 5 = 0.30 ml (30 units)
• 2 mg dose: 2 ÷ 5 = 0.40 ml (40 units)

Because PT-141 is an as-needed peptide rather than a daily protocol, many researchers prefer reconstituting with 4 ml BAC water to yield a 2.5 mg/ml concentration. This lower concentration allows finer dose titration, particularly useful when assessing initial tolerance:

• 0.5 mg dose at 2.5 mg/ml: 0.20 ml (20 units) — easier to measure accurately
• 1 mg dose at 2.5 mg/ml: 0.40 ml (40 units)

Use the PT-141 calculator above to compute precise injection volumes for any combination of vial size, BAC water volume, and target dose.

Dosing Protocol

PT-141 is structurally distinct from most research peptides in that it is an as-needed compound rather than a daily administration protocol. Its effects are not cumulative in the same way as peptides targeting chronic biological processes; each administration produces an acute pharmacological effect with a defined onset, peak, and duration.

As-Needed Protocol (Subcutaneous)

• Initial test dose: 0.5 mg subcutaneously to assess individual tolerance, blood pressure response, and gastrointestinal sensitivity before advancing to full doses
• Standard research dose: 1–2 mg subcutaneously
• Timing: Administer 30–60 minutes before the desired effect window; peak effect is typically reached 2–4 hours post-injection
• Duration of effect: 6–12 hours, with considerable individual variation
• Maximum frequency: The Vyleesi clinical trial protocol limits use to a maximum of 8 administrations per month; excessive frequency risks tachyphylaxis (rapid tolerance development)
• Injection site: Abdomen (preferred, at least 5 cm from navel), thigh, or flank; rotate sites with each administration

Important Protocol Considerations

Because PT-141 can transiently elevate blood pressure (average systolic increase of 6–10 mmHg in clinical trials), the first administration should be conducted in a calm, controlled environment. Individuals with pre-existing cardiovascular conditions, uncontrolled hypertension, or those taking antihypertensive medications should approach PT-141 research with particular caution and appropriate monitoring.

Nausea, the most commonly reported side effect, is strongly dose-dependent and typically peaks 1–2 hours post-injection. Maintaining adequate hydration before and after administration and avoiding alcohol consumption on the day of use significantly reduces nausea incidence. Starting with the 0.5 mg test dose and gradually titrating to the therapeutic range across separate sessions is the recommended approach for minimizing first-dose nausea.

Reconstitution

PT-141 is supplied as a lyophilized powder that must be reconstituted before use. Correct technique preserves peptide stability and ensures accurate dosing:

1. Gather materials: PT-141 vial, bacteriostatic water, a 1 ml or 3 ml syringe with 18–21 gauge needle for reconstitution, fine-gauge insulin syringe for injection, and alcohol swabs.
2. Sterilize stoppers: Wipe the rubber stopper of both the PT-141 vial and the BAC water vial with separate alcohol swabs. Allow to dry for a minimum of 30 seconds.
3. Draw bacteriostatic water: Draw 2 ml (or 4 ml for a more dilute concentration) of BAC water into the reconstitution syringe.
4. Inject along the vial wall: Insert the needle at an angle into the peptide vial stopper and slowly allow the BAC water to run down the inner glass wall. Never inject the water directly onto the lyophilized powder; the impact force can disrupt peptide secondary structure and reduce bioactivity.
5. Dissolve without agitation: Gently swirl the vial or roll it between your palms until the powder dissolves completely. Do not shake. Dissolution typically completes within 60–90 seconds.
6. Inspect before use: The reconstituted solution should be clear and colorless. Discard any vial with visible particulate matter, cloudiness, or unexpected coloration, as these indicate degradation or contamination.
7. Label immediately: Record the reconstitution date and the calculated concentration on the vial label.

Storage and Stability

PT-141's cyclic structure confers greater metabolic stability than many linear peptides, but appropriate storage conditions remain essential for preserving research-grade quality:

• Lyophilized powder (unreconstituted): Stable at room temperature (up to 25°C) for up to 24 months in a dry, sealed vial away from direct light. For long-term storage exceeding 6 months, refrigerate at 2–8°C. Freezing at -20°C is suitable for storage beyond 24 months.
• Reconstituted solution: Store at 2–8°C (refrigerator), upright and protected from light. With bacteriostatic water, the reconstituted solution remains usable for up to 28 days. Sterile water (without benzyl alcohol preservative) limits usability to 24–48 hours and is not recommended for PT-141.
• Light sensitivity: PT-141 has moderate sensitivity to UV light. Store in the original vial or wrap with foil if the vial is stored where it may be exposed to ambient light.
• Freeze-thaw: Do not freeze reconstituted solutions. Freeze-thaw cycles cause irreversible peptide aggregation. If a reconstituted vial will not be used within 28 days, discard and reconstitute fresh.
• Travel: Use an insulated cooler with ice pack for travel exceeding 2–3 hours. Commercial peptide travel pouches maintain appropriate temperatures for 24–48 hours.

Side Effects and Safety Considerations

PT-141 has an established safety profile from both Phase II/III clinical trials for the FDA-approved Vyleesi indication and the broader research literature. Understanding the side effect profile allows for risk-minimizing protocol design.

Common (Reported in over 10% of Clinical Trial Participants)

• Nausea: The most frequently reported side effect. Onset is typically 1–2 hours post-injection; duration is 2–4 hours. Severity correlates with dose and decreases with subsequent administrations as individual tolerance establishes.
• Flushing: Transient skin reddening, most prominent on the face, neck, and chest. Typically brief (30–60 minutes) and reflects peripheral vasodilation.
• Transient hypertension: Average systolic blood pressure increase of 6–10 mmHg, peaking 30–90 minutes post-injection and resolving within 4–6 hours. Of particular importance for individuals with borderline or elevated baseline blood pressure.
• Headache: Mild to moderate in intensity; more common at doses above 1 mg.
• Injection site reactions: Redness, minor swelling, or brief discomfort at the injection site. Minimized by proper technique and site rotation.

Less Common

• Fatigue or somnolence: Reported by a minority of users, particularly with higher doses. Avoid operating machinery or driving for several hours after administration.
• Increased heart rate: Mild tachycardia accompanying the blood pressure response; typically self-limiting and resolves without intervention.
• Hyperpigmentation: With prolonged or frequent use, transient changes in skin pigmentation may occur due to residual MC1R activity. This effect is reversible upon discontinuation.
• Gastrointestinal discomfort: Nausea may be accompanied by mild cramping or loose stools in some individuals.

Contraindications

• Individuals with uncontrolled hypertension should not use PT-141 due to the transient blood pressure elevation
• Avoid concomitant use with antihypertensive medications without physician oversight, as the pressor effect of PT-141 may complicate blood pressure management
• Not for use during pregnancy or breastfeeding
• Avoid concurrent use with other melanocortin agonists to prevent additive receptor stimulation and unpredictable response amplification
• Individuals with significant cardiovascular disease should consult a physician before any research use

Combinations and Related Peptides

PT-141's central mechanism of action is largely non-overlapping with most other research peptides, which operate through peripheral or systemic pathways. The following combinations are discussed in the research literature:

• PT-141 + Oxytocin: Oxytocin modulates social bonding, intimacy, and the reward aspects of sexual interaction. Because PT-141 already stimulates oxytocin release through MC4R activation, exogenous oxytocin addition creates potential for compounding central effects. Research on this combination is preliminary and warrants careful dose management.
• PT-141 + BPC-157:BPC-157's modulatory effects on the nitric oxide system and vascular function have led some researchers to combine it with PT-141 to investigate complementary central and peripheral mechanisms in the sexual response system.
• Selank — An anxiolytic peptide that modulates the GABAergic system. Reducing anxiety-related inhibition of sexual response is a theoretically complementary approach to PT-141's positive central activation. Selank is researched for its adaptogenic and stress-reducing properties.
• MOTS-c — While operating through different primary mechanisms, MOTS-c's metabolic and mitochondrial effects may support the overall biological context for sexual health, particularly in older populations where metabolic decline contributes to sexual dysfunction.

PT-141 vs. FDA-Approved Vyleesi: Key Differences

Understanding the relationship between research PT-141 and the FDA-approved pharmaceutical Vyleesi is important context for accurate literature interpretation:

• Formulation: Vyleesi is an autoinjector subcutaneous formulation at 1.75 mg per dose in a prefilled syringe. Research-grade PT-141 is lyophilized powder requiring reconstitution.
• Approved indication: Vyleesi is approved specifically for premenopausal women with acquired, generalized HSDD — not for general enhancement or male use.
• Dose: The approved Vyleesi dose is 1.75 mg. Research protocols explore a wider range of 0.5–2 mg.
• Regulatory status: Research-grade PT-141 is not a licensed pharmaceutical and is intended strictly for laboratory research purposes, not human therapeutic use outside of approved clinical settings.

Frequently Asked Questions

How does PT-141 differ from Viagra or Cialis?

PDE5 inhibitors (sildenafil, tadalafil) act peripherally by preventing the breakdown of cyclic GMP in vascular smooth muscle, prolonging vasodilation in the genitals during sexual stimulation. They require arousal to function — they facilitate the vascular response but do not generate desire. PT-141 acts centrally in the hypothalamus through MC3R and MC4R receptors, activating the neurological desire and motivation component of the sexual response. This means PT-141 can produce effects independent of direct genital stimulation and operates through a completely different biological pathway. The two approaches are pharmacologically non-overlapping and may theoretically be complementary, though concurrent use warrants careful oversight.

How long does PT-141 take to work?

Onset of effects is typically 30–60 minutes post-subcutaneous injection. Peak pharmacological effect is generally experienced 2–4 hours after administration. Total duration of effect ranges from 6–12 hours, with significant inter-individual variability. Factors influencing response timing include body composition, injection site, hydration status, and individual receptor sensitivity.

Can PT-141 be used daily?

Daily use is not recommended and is contrary to the clinical evidence base. The Vyleesi approval limits use to a maximum of 8 times per month. Daily administration significantly increases the risk of tachyphylaxis (rapid tolerance development), persistent nausea, blood pressure dysregulation, and hyperpigmentation. PT-141 is an as-needed compound designed for infrequent use.

Does PT-141 affect hormone levels?

PT-141 does not directly modulate the hypothalamic-pituitary-gonadal (HPG) axis or suppress endogenous steroid hormone production. It stimulates oxytocin release through MC4R activation in the paraventricular nucleus, but this is a transient effect that does not constitute endocrine suppression. No post-cycle therapy is required.

Is PT-141 effective in both men and women?

The clinical evidence is strongest for women with HSDD, which led to the FDA approval of Vyleesi for this indication. Research in men with erectile dysfunction has shown positive effects in trials where standard PDE5 inhibitors were ineffective, suggesting utility in psychogenic or central-deficit erectile dysfunction. The underlying MC3R/MC4R mechanism is present in both sexes, and both animal and human research supports central pro-sexual effects across sexes, though the magnitude and quality of response varies individually.

What is the difference between PT-141 and Melanotan II?

Both compounds act as melanocortin receptor agonists, but with different receptor affinity profiles. Melanotan II has significant MC1R agonism in addition to MC3R and MC4R activity; MC1R drives skin pigmentation (tanning), which is why MT-II users frequently experience darkening of the skin and moles. PT-141 was specifically modified from MT-II to reduce MC1R affinity while preserving the pro-sexual MC3R/MC4R effects. As a result, PT-141 has substantially less pigmentation-related activity, though at very high or prolonged doses some residual pigmentation effect can occur.

Where can I find PT-141 for research purposes?

BergdorfBio offers research-grade PT-141 in lyophilized form. You can order directly from the product page: PT-141 at BergdorfBio.

What should I monitor during first use?

For a first administration, researchers recommend:

• Beginning with the 0.5 mg tolerance-test dose, not the full research dose
• Measuring blood pressure before injection and again 30–60 minutes post-injection
• Remaining in a safe, relaxed environment for at least 2 hours post-injection
• Staying well-hydrated to minimize nausea
• Avoiding alcohol on the day of administration
• Not driving or operating heavy machinery for several hours after administration
• Having a companion present during the first use session

Medical Disclaimer:The information on this page is provided for educational and research purposes only. PT-141 (Bremelanotide) is not an approved drug or medical treatment for general use. It is sold strictly for research purposes. Nothing on this page constitutes medical advice, diagnosis, or a recommendation to use any specific compound. Always consult a qualified healthcare professional before beginning any peptide protocol. BergdorfBio assumes no liability for the use or misuse of the information presented here. Regulations regarding research chemicals vary by jurisdiction; it is the purchaser's responsibility to verify compliance with applicable local laws.